Algernon Pharmaceuticals (OTCMKTS:AGNPF – Get Free Report) is expected to be posting its resultson Friday, July 24th. Analysts expect Algernon Pharmaceuticals to post earnings of ($4.9720) per share for the quarter.
Algernon Pharmaceuticals Price Performance
Shares of OTCMKTS AGNPF opened at $0.28 on Friday. Algernon Pharmaceuticals has a fifty-two week low of $0.23 and a fifty-two week high of $0.64. The company has a 50 day simple moving average of $0.31 and a two-hundred day simple moving average of $0.15.
Algernon Pharmaceuticals Company Profile
Algernon Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel, small-molecule therapeutics. The company’s primary strategy centers on repurposing known compounds with established safety profiles to address unmet medical needs, particularly in the realms of pulmonary fibrosis, acute lung injury and central nervous system (CNS) disorders. By leveraging existing pharmacology data, Algernon aims to accelerate its development timelines while managing costs and risks typically associated with early-stage drug discovery.
The lead asset in Algernon’s pipeline is NP-120 (ifenprodil), an orally available small molecule being investigated for idiopathic pulmonary fibrosis (IPF).
Featured Articles
- Five stocks we like better than Algernon Pharmaceuticals
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for Algernon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Algernon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
